We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Recombinant Antigen-Based ELISA Evaluated for Syphilis

By LabMedica International staff writers
Posted on 28 Aug 2013
Print article
Image: Photomicrograph of Treponema pallidum (Photo courtesy of Susan Lindsley).
Image: Photomicrograph of Treponema pallidum (Photo courtesy of Susan Lindsley).
The diagnostic performance of the latest screening enzyme-linked immunosorbent assay (ELISA) for syphilis has been compared with the currently used treponemal tests.

The etiological agent of syphilis, Treponema pallidum, cannot be cultured and there is no single optimal alternative test. Serological testing is the most frequently used approach in laboratory diagnosis of the disease.

Scientists at Sekisui Virotech (Rüsselsheim, Germany) compared their Treponema pallidum Screen ELISA with standard tests. These tests included the fluorescent treponemal antibody absorption (FTA-ABS, Zeus Scientific; Branchburg, NJ, USA) test, which is an indirect fluorescent antibody technique; the T. pallidum particle agglutination (TPPA, Fujirebio; Hoofddorp, the Netherlands) test, which is a qualitative assay for the detection of antibodies to T. pallidum in serum or plasma. The most relevant test used for comparison was the Trep-Sure ELISA (Phoenix Bio-Tech Corporation; Mississauga, ON, Canada).

To establish the sensitivity and specificity of the Virotech Screen, 421 serum samples from different panels of infected and non-infected patients, sera from seronegative pregnant women as well as international syphilis standard sera and panels were tested. In comparison to combined TPPA/FTA-abs tests, Phoenix Trep-Sure and Virotech Screen demonstrated a sensitivity of 100% and a specificity of 93.9% and 98.3%, respectively.

All samples of a well-defined syphilis serum panel were correctly identified by the Virotech test, whereas the Phoenix test identified two Treponema negative samples as equivocal. The Trep Sure test is approved by the US Food and Drug Administration (FDA; Silver Springs, MD, USA). Results of both ELISAs highly correlated with TPPA negative and positive samples. The analytical sensitivity of the Virotech Screen with international standards was determined at 0.02 IU/mL and 0.03 IU/mL, and was slightly superior to the Phoenix Trep-Sure.

The authors concluded that the Virotech Screen ELISA demonstrated good diagnostic sensitivity and specificity when evaluated as a screening test for syphilis among various patient populations, including samples with increased rates of false positive nontreponemal test results. The Virotech ELISA may be used in automatic analyzers as an alternative to the manual TPPA. However, the use of a confirmatory test remains a must in order to avoid false-positive results. The study was published in the May/June, 2013 issue of the journal Clinical Laboratory.

Related Links:

Sekisui Virotech
Zeus Scientific
Fujirebio


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
New
H-FABP Test
Finecare H-FABP Rapid Quantitative Test
New
Newborn Screening Test
NeoMass AAAC 3.0

Print article

Channels

Molecular Diagnostics

view channel
Image: This joint effort will use samples from KU ADRC research to validate a blood test developed by BYU (Photo courtesy of KU ADRC)

Blood Test for Early Alzheimer’s Detection Could Help Slow Disease Progression

When brain cells, such as those affected by Alzheimer’s disease, die, small fragments of DNA are released into the bloodstream. These fragments, known as cell-free DNA, carry valuable information, including... Read more

Hematology

view channel
Image: Personalized blood count could lead to early intervention for common diseases (Photo courtesy of 123RF)

Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals

A complete blood count (CBC) screening is a standard examination most physicians request for healthy adults. This test is essential for evaluating a patient’s overall health with a single blood sample.... Read more

Microbiology

view channel
Image: The BIOFIRE® FILMARRAY® Tropical Fever Panel has received U.S. FDA Special 510(k) clearance (Photo courtesy of bioMérieux)

Syndromic PCR Test Rapidly and Accurately Identifies Pathogens in Patients with Tropical Fever Infections

Tropical fevers refer to infections that are common in, or unique to, tropical and subtropical regions. As these diseases spread to previously unaffected areas and can be brought in by travelers, infections... Read more

Pathology

view channel
Image: These images show the high resolution achieved with the new microscopy technique (Photo courtesy of Cao, R. et al. Science Advance, 2024. Caltech)

New Microscopy Technique Enables Rapid Tumor Analysis by Surgeons in OR

The current standard method for quickly sampling and imaging tissue during surgery involves taking a biopsy, freezing the sample, staining it to enhance visibility, and slicing it into thin sections that... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.